HK1044798A1 - Her-2/neu fusion proteins. - Google Patents
Her-2/neu fusion proteins.Info
- Publication number
- HK1044798A1 HK1044798A1 HK02106267A HK02106267A HK1044798A1 HK 1044798 A1 HK1044798 A1 HK 1044798A1 HK 02106267 A HK02106267 A HK 02106267A HK 02106267 A HK02106267 A HK 02106267A HK 1044798 A1 HK1044798 A1 HK 1044798A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fusion proteins
- neu
- neu fusion
- nucleic acid
- acid molecules
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11797699P | 1999-01-29 | 1999-01-29 | |
PCT/US2000/002164 WO2000044899A1 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1044798A1 true HK1044798A1 (en) | 2002-11-01 |
Family
ID=22375831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02106267A HK1044798A1 (en) | 1999-01-29 | 2002-08-26 | Her-2/neu fusion proteins. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1147190B1 (cs) |
JP (1) | JP5164300B2 (cs) |
KR (1) | KR100766653B1 (cs) |
CN (1) | CN1201004C (cs) |
AT (1) | ATE474048T1 (cs) |
AU (1) | AU780109B2 (cs) |
BR (1) | BR0007840A (cs) |
CA (1) | CA2361009C (cs) |
CZ (1) | CZ20012587A3 (cs) |
DE (1) | DE60044665D1 (cs) |
ES (1) | ES2348708T3 (cs) |
HK (1) | HK1044798A1 (cs) |
HU (1) | HUP0105303A2 (cs) |
IL (1) | IL144371A0 (cs) |
MX (1) | MXPA01007721A (cs) |
NO (1) | NO20013701L (cs) |
NZ (1) | NZ513062A (cs) |
TR (1) | TR200102191T2 (cs) |
WO (1) | WO2000044899A1 (cs) |
ZA (1) | ZA200106179B (cs) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
WO2001023421A2 (en) | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
WO2001048205A2 (en) * | 1999-12-29 | 2001-07-05 | Corixa Corporation | Murine neu sequences and methods of use therefor |
AU4791901A (en) * | 2000-03-30 | 2001-10-15 | Dendreon Corp | Compositions and methods for dendritic cell-based immunotherapy |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
KR20030048009A (ko) * | 2000-08-14 | 2003-06-18 | 코릭사 코포레이션 | Her-2/neu 관련 악성 종양의 치료 및 진단용 조성물및 방법 |
PL211151B1 (pl) | 2000-10-18 | 2012-04-30 | Glaxosmithkline Biolog Sa | Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu |
CN100548373C (zh) * | 2000-10-18 | 2009-10-14 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
WO2003005952A2 (en) | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
WO2004067716A2 (en) | 2003-01-24 | 2004-08-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer |
WO2005046571A2 (en) | 2003-06-06 | 2005-05-26 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
NZ544017A (en) * | 2003-06-25 | 2008-04-30 | Pharmexa As | A method for purification of an EGFR family derived protein recombinantly produced in an insect cell culture. |
CN101094864A (zh) | 2003-06-25 | 2007-12-26 | 法麦克萨有限公司 | Her-2变体的纯化 |
JP4772674B2 (ja) * | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途 |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
PE20080742A1 (es) | 2006-06-02 | 2008-08-06 | Glaxosmithkline Biolog Sa | Perfil genico y procedimiento de identificacion |
EA201300102A1 (ru) | 2007-05-24 | 2014-02-28 | Глаксосмитклайн Байолоджикалс С.А. | Лиофилизированная антигенная композиция |
AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
KR101992502B1 (ko) | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
EP2750713B1 (en) | 2011-10-14 | 2015-09-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
BR112015008173A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolobenzodiazepina-anticorpo anti-psma |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
SI2839860T1 (sl) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pirolobenzodiazepini in njihovi konjugati |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
JP6425327B2 (ja) * | 2013-12-12 | 2018-11-21 | 国立大学法人東京農工大学 | タンパク質−磁性粒子複合体及びその製造方法 |
CN107106700B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック, インコーポレイテッド | 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3191134B1 (en) | 2014-09-12 | 2019-11-20 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA2959689A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
AU2015358532C1 (en) | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP4273551A3 (en) | 2016-03-25 | 2024-01-17 | F. Hoffmann-La Roche AG | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
CN110536703A (zh) | 2017-04-20 | 2019-12-03 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
CN111065638B (zh) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
MX2023000622A (es) * | 2020-07-14 | 2023-02-22 | Genentech Inc | Ensayos para combinaciones de dosis fija. |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
KR102584276B1 (ko) * | 2023-03-30 | 2023-10-10 | 주식회사 애스톤사이언스 | Her2 백신, 및 면역관문 억제제의 조합 요법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0474727B1 (en) * | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
JPH0914357A (ja) * | 1995-06-27 | 1997-01-14 | Honda Motor Co Ltd | 伝動ベルト用ブロック |
-
2000
- 2000-01-28 NZ NZ513062A patent/NZ513062A/en unknown
- 2000-01-28 CN CNB008057524A patent/CN1201004C/zh not_active Expired - Fee Related
- 2000-01-28 MX MXPA01007721A patent/MXPA01007721A/es not_active Application Discontinuation
- 2000-01-28 JP JP2000596141A patent/JP5164300B2/ja not_active Expired - Fee Related
- 2000-01-28 AU AU27426/00A patent/AU780109B2/en not_active Ceased
- 2000-01-28 DE DE60044665T patent/DE60044665D1/de not_active Expired - Lifetime
- 2000-01-28 BR BR0007840-9A patent/BR0007840A/pt not_active IP Right Cessation
- 2000-01-28 AT AT00905800T patent/ATE474048T1/de not_active IP Right Cessation
- 2000-01-28 IL IL14437100A patent/IL144371A0/xx unknown
- 2000-01-28 ES ES00905800T patent/ES2348708T3/es not_active Expired - Lifetime
- 2000-01-28 CA CA2361009A patent/CA2361009C/en not_active Expired - Fee Related
- 2000-01-28 EP EP00905800A patent/EP1147190B1/en not_active Expired - Lifetime
- 2000-01-28 TR TR2001/02191T patent/TR200102191T2/xx unknown
- 2000-01-28 CZ CZ20012587A patent/CZ20012587A3/cs unknown
- 2000-01-28 WO PCT/US2000/002164 patent/WO2000044899A1/en not_active Application Discontinuation
- 2000-01-28 KR KR1020017009563A patent/KR100766653B1/ko not_active IP Right Cessation
- 2000-01-28 HU HU0105303A patent/HUP0105303A2/hu unknown
-
2001
- 2001-07-26 ZA ZA200106179A patent/ZA200106179B/en unknown
- 2001-07-27 NO NO20013701A patent/NO20013701L/no unknown
-
2002
- 2002-08-26 HK HK02106267A patent/HK1044798A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1345374A (zh) | 2002-04-17 |
NO20013701L (no) | 2001-09-28 |
AU780109B2 (en) | 2005-03-03 |
AU2742600A (en) | 2000-08-18 |
MXPA01007721A (es) | 2003-07-14 |
CA2361009A1 (en) | 2000-08-03 |
JP2002535004A (ja) | 2002-10-22 |
WO2000044899A1 (en) | 2000-08-03 |
NO20013701D0 (no) | 2001-07-27 |
NZ513062A (en) | 2003-10-31 |
CN1201004C (zh) | 2005-05-11 |
EP1147190A1 (en) | 2001-10-24 |
DE60044665D1 (de) | 2010-08-26 |
ES2348708T3 (es) | 2010-12-13 |
KR20010101865A (ko) | 2001-11-15 |
CZ20012587A3 (cs) | 2002-05-15 |
CA2361009C (en) | 2012-10-23 |
TR200102191T2 (tr) | 2001-12-21 |
ZA200106179B (en) | 2002-12-24 |
HUP0105303A2 (en) | 2002-05-29 |
KR100766653B1 (ko) | 2007-10-15 |
IL144371A0 (en) | 2002-05-23 |
ATE474048T1 (de) | 2010-07-15 |
BR0007840A (pt) | 2002-01-22 |
JP5164300B2 (ja) | 2013-03-21 |
EP1147190B1 (en) | 2010-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1044798A1 (en) | Her-2/neu fusion proteins. | |
WO2002012341A3 (en) | Her-2/neu fusion proteins | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
TW428026B (en) | Bifunctional protein, preparation and use | |
FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
BR9608615A (pt) | Vacinas de vírus sincicial respiratório de ácido nucléico | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
EP1408986A4 (en) | PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
WO2004030636A3 (en) | Human papillomavirus polypeptides and immunogenic compositions | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
DE69924826T8 (de) | Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie | |
ATE228016T1 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
WO2003093298A3 (en) | Immunogenic peptides | |
ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
WO2001055391A3 (en) | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100128 |